Cost-Minimization Analysis of Direct Cost of Sevelamer Carbonate and Lanthanum Carbonate in the Treatment of Patients with Chronic Kidney Disease Not on Dialysis in Bulgaria Martin Petrov, MSc, Maria Dimitrova, PhD, Guenka Petrova, DSc Value in Health Regional Issues Volume 7, Pages 94-103 (September 2015) DOI: 10.1016/j.vhri.2015.09.004 Copyright © 2015 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions
Fig. 1 Tornado diagram presenting the changes in cost savings when individual parameter values are varied (4000 mg SC vs. 2000 mg LC dose regimens for patient allocation SC 100% vs. SC 50%:LC 50%). LC, lanthanum carbonate; SC, sevelamer carbonate. Value in Health Regional Issues 2015 7, 94-103DOI: (10.1016/j.vhri.2015.09.004) Copyright © 2015 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions
Fig. 2 Tornado diagram presenting the changes in cost savings when individual parameter values are varied (4000 mg SC vs. 2000 mg LC dose regimens for patient allocation SC 100% vs. LC 100%). LC, lanthanum carbonate; SC, sevelamer carbonate. Value in Health Regional Issues 2015 7, 94-103DOI: (10.1016/j.vhri.2015.09.004) Copyright © 2015 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions